



Symposium of Western Australian Neuroscience 2018

Harry Perkins Institute of Medical Research Auditorium

PUBLIC LECTURE

Proudly sponsored by ...



During his >30 years in the pharmaceutical industry Dr Dan Burns has worked across the continuum of discovery and development of medicines and their post approval life cycle management. He has led in house scientific departments at large pharmaceutical companies while also building successful collaborations with the biotechnology industry, government, patient advocacy groups and public private partnerships.

As a senior executive at Zinfandel Pharmaceuticals, Dan leads a team in alliance with Takeda Pharmaceuticals responsible for the design and execution of a global phase 3 registration study to simultaneously qualify a genetic biomarker and evaluate a therapeutic to delay the onset of Alzheimer's disease. Prior to his appointment at Zinfandel Pharmaceuticals, he served in senior management positions at GlaxoSmithKline (GSK), most recently as Senior Vice President, Pharmacogenomics. In addition to managing international line functions, he took a leadership role in working across therapeutic areas to integrate pharmacogenetics throughout the R&D organisation. Prior to joining GSK he held positions of increasing responsibility at Hoffmann-La Roche, Inc.

Dan Burns has published widely throughout his career and has been an invited speaker on the topic of pharmacogenetics, biomarkers and innovation in drug development at numerous scientific conferences. These include meetings organized by the US Food and Drug Administration (FDA), the National Institutes of Health (NIH), Drug Information Association (DIA) and the Keystone Symposium. In addition, he has provided consultation services to the pharmaceutical and diagnostic industries.

Dr Burns holds a BS (Biology), MA (Zoology) and PhD (Molecular, Cellular and Developmental Biology) from Indiana University. He did his post-doctoral research at Hoffmann-La Roche, Inc. investigating protein structure function relationships.



**Dr Dan Burns
Zinfandel**

Pharmaceuticals Inc. (USA)

**'25 Years of Alzheimer's
disease Research and Clinical
Development: How we got
here and where do we go'**

4.20pm on Friday, 30 November
Harry Perkins Institute of Medical
Research Auditorium

JOIN US FROM 3.20PM!

This lecture is part of a session
open to the general public and
will commence with a
**THREE-MINUTE THESIS
COMPETITION (HONS & EARLY
PHD STUDENTS)** from 3.20PM.
ALL ARE WELCOME!

